Tadashi Shimizu

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Combination Therapy

Cross Sectional

Top Venues

Journal of clinical pharmacy and therapeutics

Life (Basel, Switzerland)

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Kenta Yamaoka, Nobuyuki Katakami, Nobuhiro Hiramoto, Masaki Hirabatake, Hiroaki Ikesue, Tohru Hashida, Tadashi Shimizu, Takayuki Ishikawa, Nobuyuki Muroi
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma. Investigational new drugs (2023)
Mayako Uchida, Kana Nakano, Masaki Fujiwara, Yoshihiro Uesawa, Tadashi Shimizu
Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database. Journal of clinical pharmacy and therapeutics 47 (8) (2022)
Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu
Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. Life (Basel, Switzerland) 12 (9) (2022)